| pubmed-article:9597571 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:9597571 | lifeskim:mentions | umls-concept:C0006142 | lld:lifeskim |
| pubmed-article:9597571 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:9597571 | lifeskim:mentions | umls-concept:C0008976 | lld:lifeskim |
| pubmed-article:9597571 | lifeskim:mentions | umls-concept:C0034656 | lld:lifeskim |
| pubmed-article:9597571 | lifeskim:mentions | umls-concept:C0079459 | lld:lifeskim |
| pubmed-article:9597571 | lifeskim:mentions | umls-concept:C1518999 | lld:lifeskim |
| pubmed-article:9597571 | lifeskim:mentions | umls-concept:C0010583 | lld:lifeskim |
| pubmed-article:9597571 | lifeskim:mentions | umls-concept:C0015133 | lld:lifeskim |
| pubmed-article:9597571 | lifeskim:mentions | umls-concept:C0178602 | lld:lifeskim |
| pubmed-article:9597571 | lifeskim:mentions | umls-concept:C0300926 | lld:lifeskim |
| pubmed-article:9597571 | lifeskim:mentions | umls-concept:C1306673 | lld:lifeskim |
| pubmed-article:9597571 | pubmed:issue | 2 | lld:pubmed |
| pubmed-article:9597571 | pubmed:dateCreated | 1998-8-4 | lld:pubmed |
| pubmed-article:9597571 | pubmed:abstractText | The purpose of this study was to develop a less toxic outpatient chemotherapy regimen for mobilizing peripheral blood stem cells (PBSC). Three hundred eighteen patients with newly diagnosed stage II-III breast cancer who had received conventional dose adjuvant chemotherapy were randomized to receive intermediate-dose cyclophosphamide (2 g/m2), etoposide (600 mg/m2), and granulocyte colony-stimulating factor (G-CSF) 6 micrograms/kg/day (ID-Cy, n = 162) or high-dose cyclophosphamide (4 g/m2) and the same doses of etoposide and G-CSF (HD-Cy, n = 156) followed by collection of PBSC. Three hundred seventeen of 318 patients had apheresis performed, and 315 received high-dose chemotherapy (HDC) followed by PBSC support. The median numbers of CD34+ cells collected in a median of two apheresis following ID-Cy and HD-Cy were 19.9 and 22.2 x 10(6)/kg, respectively (p = 0.04). The fractions of patients achieving CD34+ cell doses > or = 2.5 or > or = 5.0 x 10(6)/kg were not different between the two regimens. More patients receiving HD-Cy had grade 3-4 nausea (p = 0.001), vomiting (p = 0.03), and mucositis (p = 0.04). The fractions of patients having a neutrophil nadir < 0.5 x 10(9)/L following ID-Cy and HD-Cy were 0.83 and 0.95, respectively (p = < 0.001). The fractions of patients having a platelet nadir < 25 x 10(9)/L following ID-Cy and HD-Cy were 0.13 and 0.51, respectively (p = < 0.001). More patients in the HD-Cy group received platelet (p < 0.001) and red blood cell (p < 0.001) transfusions and were admitted to the hospital more frequently (p = 0.03) than patients receiving ID-Cy. Three hundred fifteen patients received HDC followed by infusion of PBSC. There were no significant differences in the incidence of transplant-related death or early survival between patients receiving ID-Cy or HD-Cy followed by HDC. It was concluded that a regimen of Cy 2 g/m2 with etoposide and G-CSF was effective for mobilization of PBSC with low morbidity and resource utilization in patients with limited prior chemotherapy exposure. | lld:pubmed |
| pubmed-article:9597571 | pubmed:language | eng | lld:pubmed |
| pubmed-article:9597571 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9597571 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:9597571 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9597571 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9597571 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9597571 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9597571 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:9597571 | pubmed:month | Apr | lld:pubmed |
| pubmed-article:9597571 | pubmed:issn | 1061-6128 | lld:pubmed |
| pubmed-article:9597571 | pubmed:author | pubmed-author:BucknerC DCD | lld:pubmed |
| pubmed-article:9597571 | pubmed:author | pubmed-author:SmithRR | lld:pubmed |
| pubmed-article:9597571 | pubmed:author | pubmed-author:LeffRR | lld:pubmed |
| pubmed-article:9597571 | pubmed:author | pubmed-author:SchwartzbergL... | lld:pubmed |
| pubmed-article:9597571 | pubmed:author | pubmed-author:BirchRR | lld:pubmed |
| pubmed-article:9597571 | pubmed:author | pubmed-author:HainsworthJJ | lld:pubmed |
| pubmed-article:9597571 | pubmed:author | pubmed-author:GrecoTT | lld:pubmed |
| pubmed-article:9597571 | pubmed:author | pubmed-author:TauerKK | lld:pubmed |
| pubmed-article:9597571 | pubmed:author | pubmed-author:MurphyM NMN | lld:pubmed |
| pubmed-article:9597571 | pubmed:author | pubmed-author:BeekerTT | lld:pubmed |
| pubmed-article:9597571 | pubmed:author | pubmed-author:WeaverC HCH | lld:pubmed |
| pubmed-article:9597571 | pubmed:author | pubmed-author:MannerCC | lld:pubmed |
| pubmed-article:9597571 | pubmed:author | pubmed-author:Morgan-IhrigC... | lld:pubmed |
| pubmed-article:9597571 | pubmed:author | pubmed-author:SchwerkoskeJJ | lld:pubmed |
| pubmed-article:9597571 | pubmed:author | pubmed-author:MacAnenyBB | lld:pubmed |
| pubmed-article:9597571 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:9597571 | pubmed:volume | 7 | lld:pubmed |
| pubmed-article:9597571 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:9597571 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:9597571 | pubmed:pagination | 141-50 | lld:pubmed |
| pubmed-article:9597571 | pubmed:dateRevised | 2006-4-24 | lld:pubmed |
| pubmed-article:9597571 | pubmed:meshHeading | pubmed-meshheading:9597571-... | lld:pubmed |
| pubmed-article:9597571 | pubmed:meshHeading | pubmed-meshheading:9597571-... | lld:pubmed |
| pubmed-article:9597571 | pubmed:meshHeading | pubmed-meshheading:9597571-... | lld:pubmed |
| pubmed-article:9597571 | pubmed:meshHeading | pubmed-meshheading:9597571-... | lld:pubmed |
| pubmed-article:9597571 | pubmed:meshHeading | pubmed-meshheading:9597571-... | lld:pubmed |
| pubmed-article:9597571 | pubmed:meshHeading | pubmed-meshheading:9597571-... | lld:pubmed |
| pubmed-article:9597571 | pubmed:meshHeading | pubmed-meshheading:9597571-... | lld:pubmed |
| pubmed-article:9597571 | pubmed:meshHeading | pubmed-meshheading:9597571-... | lld:pubmed |
| pubmed-article:9597571 | pubmed:meshHeading | pubmed-meshheading:9597571-... | lld:pubmed |
| pubmed-article:9597571 | pubmed:meshHeading | pubmed-meshheading:9597571-... | lld:pubmed |
| pubmed-article:9597571 | pubmed:meshHeading | pubmed-meshheading:9597571-... | lld:pubmed |
| pubmed-article:9597571 | pubmed:meshHeading | pubmed-meshheading:9597571-... | lld:pubmed |
| pubmed-article:9597571 | pubmed:meshHeading | pubmed-meshheading:9597571-... | lld:pubmed |
| pubmed-article:9597571 | pubmed:meshHeading | pubmed-meshheading:9597571-... | lld:pubmed |
| pubmed-article:9597571 | pubmed:meshHeading | pubmed-meshheading:9597571-... | lld:pubmed |
| pubmed-article:9597571 | pubmed:meshHeading | pubmed-meshheading:9597571-... | lld:pubmed |
| pubmed-article:9597571 | pubmed:year | 1998 | lld:pubmed |
| pubmed-article:9597571 | pubmed:articleTitle | A randomized trial of two doses of cyclophosphamide with etoposide and G-CSF for mobilization of peripheral blood stem cells in 318 patients with stage II-III breast cancer. | lld:pubmed |
| pubmed-article:9597571 | pubmed:affiliation | Clinical Trials Division of Response Oncology, Inc., Memphis, TN 38117, USA. | lld:pubmed |
| pubmed-article:9597571 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:9597571 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:9597571 | pubmed:publicationType | Randomized Controlled Trial | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9597571 | lld:pubmed |
